
Rafael A Vega MD PhD
Brain & Spinal Tumor, Skull Base
Director of Neurosurgical Oncology at Beth Israel Deaconess Medical Center, Harvard Medical School
Join to View Full Profile
110 Francis StLowry Suite 3BBoston, MA 02215
Phone+1 617-632-7246
Fax+1 617-632-0949
Dr. Vega is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Rafael Vega is a board-certified neurosurgeon in Boston, MA and affiliated with Beth Israel Deaconess Medical Center, Harvard Medical School. He received his fellowship training at MD Anderson in Neurosurgical Oncology. He serves as Director of the Brain Tumor Center at BIDMC and is a Member of Dana-Farber/Harvard Cancer Center. He specializes in the treatment of malignant/benign brain tumors.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Neurosurgical Oncology, 2018 - 2019
Virginia Commonwealth University Health SystemResidency, Neurological Surgery, 2011 - 2018
University of Virginia Medical CenterPost-Doctoral Fellowship, Neuro-Oncology, 2015 - 2016
University of Illinois College of MedicineClass of 2011, MD
Northwestern UniversityPhD, Chemistry of Life Processes, 2003 - 2007
Certifications & Licensure
MA State Medical License 2019 - 2027
NH State Medical License 2024 - 2024
American Board of Neurological Surgery Neurological Surgery- The Society of Neurological SurgeonsCommittee on Advanced Subspecialty Training (CAST) in Neurosurgical Oncology
Awards, Honors, & Recognition
- Boston Magazine Top Doctor 2024-2025
- Castle Connolly Top Doctor (Regional) 2023-2025
- Fellow of the American College of Surgeons (FACS) American College of Surgeons, 2024
Clinical Trials
- Surgical Pembro +/- Olaparib w TMZ for rGBM Start of enrollment: 2022 Oct 21
Roles: Contact
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Start of enrollment: 2022 Jun 20
Publications & Presentations
PubMed
- Extracellular Vesicles from Glioblastoma Cells Reflect 2D vs. 3D Culture Adaptation and Resistance to Temozolomide.Getulio Pereira de Oliveira, Alan Zimmerman, Cintia C Palu, Vivian Tran, Gabrielle Bogut
Molecular & Cellular Proteomics. 2026-06-23 - 1 citationsRethinking the role of surgical resection in the management of primary pituitary lymphoma.Jean Filo, Maryann Zhao, Eduardo Orrego-Gonzalez, Steven N Schwartz, Bartholomew White
British Journal of Neurosurgery. 2025-12-01 - Post-ablation volume threshold for brain metastasis control using LITT: a systematic review and critical appraisal.Fernando Terry, Anderson Brito, Fritz F Váscones-Román, Valeria Rivera, Alejandro Enríquez-Marulanda
Journal of Neuro-Oncology. 2025-11-17
Books/Book Chapters
Committees
- Co-Chair, CNS Journal Club Podcast 2019 - Present
Research History
- Principle Investigator, Surgical Neuro-Oncology Outcomes LaboratoryBeth Israel Deaconess Medical Center / Harvard Medical School2020 - Present
Professional Memberships
- Member
- Member
- Member
- Society of Neuro-OncologyMember
- North American Skull Base SocietyMember
Other Languages
- Spanish
External Links
- DF/HCC Profilehttps://www.dfhcc.harvard.edu/insider/member-detail/member/rafael-a-vega-md-phd/
- BIDMC Brain Tumor Centerhttps://www.bidmc.org/centers-and-departments/cancer-center/cancer-center-programs-and-services/brain-tumor-program
- BIDMC Neurosurgeryhttps://www.bidmc.org/centers-and-departments/neurosurgery
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









